» Articles » PMID: 30106382

Survival Signal REG3α Prevents Crypt Apoptosis to Control Acute Gastrointestinal Graft-versus-host Disease

Abstract

Graft-versus-host disease (GVHD) in the gastrointestinal (GI) tract remains the major cause of morbidity and nonrelapse mortality after BM transplantation (BMT). The Paneth cell protein regenerating islet-derived 3α (REG3α) is a biomarker specific for GI GVHD. REG3α serum levels rose in the systematic circulation as GVHD progressively destroyed Paneth cells and reduced GI epithelial barrier function. Paradoxically, GVHD suppressed intestinal REG3γ (the mouse homolog of human REG3α), and the absence of REG3γ in BMT recipients intensified GVHD but did not change the composition of the microbiome. IL-22 administration restored REG3γ production and prevented apoptosis of both intestinal stem cells (ISCs) and Paneth cells, but this protection was completely abrogated in Reg3g-/- mice. In vitro, addition of REG3α reduced the apoptosis of colonic cell lines. Strategies that increase intestinal REG3α/γ to promote crypt regeneration may offer a novel, nonimmunosuppressive approach for GVHD and perhaps for other diseases involving the ISC niche, such as inflammatory bowel disease.

Citing Articles

Soluble ST2 as a Predictive Biomarker for Acute Graft-Versus-Host Disease Post -Allogeneic Stem Cell Transplantation.

Huang K, Yang M, Huang J, Cao Y, Zhou Y, Pang G Clin Transplant. 2025; 39(3):e70108.

PMID: 40033972 PMC: 11877010. DOI: 10.1111/ctr.70108.


Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.

Rios C, Qayed M, Etra A, Reshef R, Newcomb R, Yuhasz N Transplant Cell Ther. 2024; 30(11):1061.e1-1061.e10.

PMID: 39222793 PMC: 11540730. DOI: 10.1016/j.jtct.2024.08.019.


Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.

Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C Blood. 2024; 144(9):1010-1021.

PMID: 38968143 PMC: 11830971. DOI: 10.1182/blood.2024025106.


The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.

DeFilipp Z, Kim H, Spyrou N, Katsivelos N, Kowalyk S, Eng G Blood Adv. 2024; 8(13):3488-3496.

PMID: 38640197 PMC: 11260849. DOI: 10.1182/bloodadvances.2024012561.


Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD.

Etra A, Jurdi N, Katsivelos N, Kwon D, Gergoudis S, Morales G Blood Adv. 2024; 8(12):3284-3292.

PMID: 38640195 PMC: 11226972. DOI: 10.1182/bloodadvances.2023011049.


References
1.
Przepiorka D, Smith T, Folloder J, Khouri I, Ueno N, Mehra R . Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999; 94(4):1465-70. View

2.
Weber D, Oefner P, Hiergeist A, Koestler J, Gessner A, Weber M . Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome. Blood. 2015; 126(14):1723-8. DOI: 10.1182/blood-2015-04-638858. View

3.
Simon M, Pauloin A, Normand G, Lieu H, Mouly H, Pivert G . HIP/PAP stimulates liver regeneration after partial hepatectomy and combines mitogenic and anti-apoptotic functions through the PKA signaling pathway. FASEB J. 2003; 17(11):1441-50. DOI: 10.1096/fj.02-1013com. View

4.
Hill G, Ferrara J . The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000; 95(9):2754-9. View

5.
Pidala J, Wang T, Haagenson M, Spellman S, Askar M, Battiwalla M . Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood. 2013; 122(22):3651-8. PMC: 3837514. DOI: 10.1182/blood-2013-05-501510. View